Logo image of GLS

GELESIS HOLDINGS INC (GLS) Stock Fundamental Analysis

USA - New York Stock Exchange - NYSE:GLS - US36850R2040 - Common Stock

0.1586 USD
+0 (+0.38%)
Last: 4/10/2023, 8:04:01 PM
0.1555 USD
0 (-1.95%)
After Hours: 4/10/2023, 8:04:01 PM
Fundamental Rating

1

GLS gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 529 industry peers in the Biotechnology industry. Both the profitability and financial health of GLS have multiple concerns. GLS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

GLS had negative earnings in the past year.
In the past year GLS has reported a negative cash flow from operations.
GLS Yearly Net Income VS EBIT VS OCF VS FCFGLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 -50M -100M -150M

1.2 Ratios

GLS has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GLS Yearly ROA, ROE, ROICGLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 0 200 400 600 800 1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GLS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GLS Yearly Profit, Operating, Gross MarginsGLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 0 -500 -1K -1.5K

More info and screens

0

2. Health

2.1 Basic Checks

GLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GLS has been increased compared to 1 year ago.
Compared to 1 year ago, GLS has a worse debt to assets ratio.
GLS Yearly Shares OutstandingGLS Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 20M 40M 60M
GLS Yearly Total Debt VS Total AssetsGLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 50M 100M 150M

2.2 Solvency

GLS has an Altman-Z score of -8.60. This is a bad value and indicates that GLS is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of GLS (-8.60) is worse than 77.97% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -8.6
ROIC/WACCN/A
WACC5.71%
GLS Yearly LT Debt VS Equity VS FCFGLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 0 50M -50M

2.3 Liquidity

GLS has a Current Ratio of 0.30. This is a bad value and indicates that GLS is not financially healthy enough and could expect problems in meeting its short term obligations.
GLS's Current ratio of 0.30 is on the low side compared to the rest of the industry. GLS is outperformed by 94.45% of its industry peers.
GLS has a Quick Ratio of 0.30. This is a bad value and indicates that GLS is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.21, GLS is doing worse than 94.93% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.3
Quick Ratio 0.21
GLS Yearly Current Assets VS Current LiabilitesGLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 20M 40M 60M 80M 100M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 66.00% over the past year.
The Revenue has grown by 80.37% in the past year. This is a very strong growth!
EPS 1Y (TTM)66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.08%
Revenue 1Y (TTM)80.37%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-76.5%

3.2 Future

Based on estimates for the next years, GLS will show a very strong growth in Earnings Per Share. The EPS will grow by 36.67% on average per year.
Based on estimates for the next years, GLS will show a very strong growth in Revenue. The Revenue will grow by 68.56% on average per year.
EPS Next Y78.59%
EPS Next 2Y36.67%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year80.41%
Revenue Next 2Y68.56%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

GLS Yearly Revenue VS EstimatesGLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 20M 40M 60M 80M
GLS Yearly EPS VS EstimatesGLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

GLS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GLS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GLS Price Earnings VS Forward Price EarningsGLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GLS Per share dataGLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as GLS's earnings are expected to grow with 36.67% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.67%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GLS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GELESIS HOLDINGS INC

NYSE:GLS (4/10/2023, 8:04:01 PM)

After market: 0.1555 0 (-1.95%)

0.1586

+0 (+0.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-23 2023-03-23/bmo
Earnings (Next)05-10 2023-05-10/bmo
Inst Owners16.44%
Inst Owner Change0%
Ins Owners24.71%
Ins Owner Change0%
Market Cap11.63M
Revenue(TTM)25.77M
Net Income(TTM)-95.06M
Analysts45
Price Target0.46 (190.04%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)41.93%
Min EPS beat(2)41.93%
Max EPS beat(2)41.93%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.45
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.31
EYN/A
EPS(NY)-0.28
Fwd EYN/A
FCF(TTM)-1.18
FCFYN/A
OCF(TTM)-1.06
OCFYN/A
SpS0.35
BVpS-0.34
TBVpS-0.52
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 166.18%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.3
Quick Ratio 0.21
Altman-Z -8.6
F-Score2
WACC5.71%
ROIC/WACCN/A
Cap/Depr(3y)616.89%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.08%
EPS Next Y78.59%
EPS Next 2Y36.67%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)80.37%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-76.5%
Revenue Next Year80.41%
Revenue Next 2Y68.56%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-18.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year16.32%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-15.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-40.58%
OCF growth 3YN/A
OCF growth 5YN/A

GELESIS HOLDINGS INC / GLS FAQ

What is the ChartMill fundamental rating of GELESIS HOLDINGS INC (GLS) stock?

ChartMill assigns a fundamental rating of 2 / 10 to GLS.


What is the valuation status for GLS stock?

ChartMill assigns a valuation rating of 0 / 10 to GELESIS HOLDINGS INC (GLS). This can be considered as Overvalued.


Can you provide the profitability details for GELESIS HOLDINGS INC?

GELESIS HOLDINGS INC (GLS) has a profitability rating of 0 / 10.


What is the financial health of GELESIS HOLDINGS INC (GLS) stock?

The financial health rating of GELESIS HOLDINGS INC (GLS) is 0 / 10.